000020 — Dongwha Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Market Cap
KR₩235bn
Enterprise Value
KR₩231bn
Revenue
KR₩361bn

Annual income statement for Dongwha Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	307,150	272,075	293,018	340,426	361,109
Cost of Revenue
Gross Profit	121,596	138,666	149,347	180,990	190,416
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	291,032	248,962	270,732	313,989	342,825
Operating Profit	16,118	23,113	22,286	26,437	18,284
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16,241	33,638	26,527	23,086	36,956
Provision for Income Taxes
Net Income After Taxes	9,108	28,715	19,583	21,591	28,237
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,116	28,508	17,870	20,383	27,438
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	9,116	28,519	17,870	20,383	27,438
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	197	803	648	847	1,004
Dividends per Share